Healthcare systems must turn proven research into patient care faster with practical infrastructure, product champions, trust ...

A recent Executive Order (EO) de-risks psychedelic drug development by clarifying regulations, but scalable treatment models ...

A “Godzilla” El Niño could disrupt pharma supply chains, pushing life sciences firms toward AI-driven weather forecasting, ...

What happened at BIO? This selected coverage from the BIO 2026 meeting in San Francisco includes highlights from panels on ...

The U.S. Food and Drug Administration’s Office of Prescription Drug Promotion's (OPDP’s) 2026 untitled letters do more than identify a handful of promotional missteps. Read together with the agency’s ...

This article was created from the author's presentation at the 2018 Bioprocessing Asia conference, with Cytiva as principal sponsor. The BioProcessing Asia Conference series was created to provide a ...

Canada has unique medical information requirements that demand professionalism, compassion, and local expertise. In this video, Larry Hough, Senior Director of Pharmacovigilance and Medical ...

On this week's episode of the Business of Biotech, Al Sandrock, M.D., Ph.D., President and CEO at Voyager Therapeutics, talks about why tau is becoming a central target in Alzheimer’s drug development ...

On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma.

Managing raw material variation and process risks is critical to ensuring a high level of quality and consistency in drug development and manufacturing. Supply chain partners across the industry must ...